another record low share price realised, and under the $2 floor, which will likely now become the ceiling given how poorly this company is managed. It looks like the market believes that the only thing Anaconda pharma has to offer is Disallowed.
And the US management is proving that the only thing they are good at is following in the footsteps.of Australian managememt.
This has been an absolutely disastrous investment choice.....
